Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Active not recruiting 1

Sponsor Class

NIH 1

Study Type

Interventional 1

Sponsor

Cancer Type

Myeloid 1Lymphoid 1Genitourinary 1Gastrointestinal 1CNS 1

Conditions

Wilms Tumor 9Glioma 9Osteosarcoma 8Neuroblastoma 8Multiple Myeloma 8Leukemia, Myeloid, Acute 8Sarcoma 7Rhabdoid Tumor 7Prostatic Neoplasms 7Neoplasm Metastasis 7Lymphoma, Non-Hodgkin 7Hepatoblastoma 7Rhabdomyosarcoma 6Neuroectodermal Tumors, Primitive, Peripheral 6Medulloblastoma 6Lymphoma 6Lung Neoplasms 6Histiocytosis, Langerhans-Cell 6Ependymoma 6Colorectal Neoplasms 6Breast Neoplasms 6Precursor Cell Lymphoblastic Leukemia-Lymphoma 5Myelodysplastic Syndromes 5Central Nervous System Neoplasms 5Carcinoma, Hepatocellular 5Sarcoma, Ewing 4Ovarian Neoplasms 4Melanoma 4Carcinoma, Non-Small-Cell Lung 4Rectal Neoplasms 3

Interventions

Specimen Handling 2Magnetic Resonance Spectroscopy 2pembrolizumab 1palbociclib 1erdafitinib 1X-Rays 1Phantoms, Imaging 1Nuclear Medicine Department, Hospital 1Diffusion Tensor Imaging 1Biopsy 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Familial ependymoma × X-Rays × 90 days × Clear all
NCT03210714 2026-06-01

Erdafitinib in Treating Patients With Relapsed or Refractory Advanced Solid Tumors, Non-Hodgkin Lymphoma, or Histiocytic Disorders With FGFR Mutations (A Pediatric MATCH Treatment Trial)

National Cancer Institute (NCI)

Phase 2 Active not recruiting
20 enrolled 10 charts
CNSGastrointestinalGenitourinaryLymphoidMyeloid

Familial ependymoma, Ependymoma, Glioma, Histiocytosis, Langerhans-Cell, Lymphoma, Non-Hodgkin, Medulloblastoma, Wilms Tumor, Neuroblastoma, Central Nervous System Neoplasms, Hepatoblastoma, Neuroectodermal Tumors, Primitive, Peripheral, Rhabdoid Tumor

Data powered by HemOnc (CC BY 4.0) Colophon âš¡